Free tool
FAERS Monitor: Otezla
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210745 or its brand name (Otezla, Apremilast). Reports on generic versions are filed under their own applications.
Reports
146,435
Serious
35,036
24% of reports
Hospitalization
11,809
Death reported
6,208
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea24,755
- nausea22,292
- psoriasis20,666
- headache18,012
- drug ineffective15,674
- abdominal discomfort8,337
- psoriatic arthropathy8,315
- pain7,045
- rash6,888
- vomiting6,639
- arthralgia6,531
- fatigue6,327
- depression5,640
- off label use5,427
- weight decreased5,094
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 1,244 |
| 2015 | 12,439 |
| 2016 | 13,932 |
| 2017 | 18,313 |
| 2018 | 19,926 |
| 2019 | 22,848 |
| 2020 | 19,781 |
| 2021 | 10,551 |
| 2022 | 7,338 |
| 2023 | 5,928 |
| 2024 | 6,024 |
| 2025 | 4,946 |
| 2026 | 3,158 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,907,724 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriatic arthropathySignal | 8,315 | 36.7 | 35.9 | 230,332 |
| psoriasisSignal | 20,666 | 26.8 | 26.4 | 434,941 |
| abdominal discomfortSignal | 8,337 | 7.5 | 7.3 | 44,665 |
| diarrhoeaSignal | 24,755 | 5.7 | 5.6 | 94,890 |
| headacheSignal | 18,012 | 4.2 | 4.2 | 44,282 |
| nauseaSignal | 22,292 | 4.1 | 4.1 | 53,477 |
| depressionSignal | 5,640 | 3.6 | 3.5 | 10,569 |
| weight decreasedSignal | 5,094 | 2.7 | 2.6 | 5,210 |
| rashSignal | 6,888 | 2.3 | 2.2 | 5,029 |
| arthralgiaSignal | 6,531 | 2.3 | 2.2 | 4,691 |
| vomitingSignal | 6,639 | 2.0 | 2.0 | 3,563 |
| drug ineffective | 15,674 | 1.7 | 1.7 | 4,944 |
| pain | 7,045 | 1.7 | 1.6 | 1,858 |
| fatigue | 6,327 | 1.2 | 1.1 | 158 |
| off label use | 5,427 | 0.9 | 0.9 | 77 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.